Nathalie Rioux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8615014/publications.pdf

Version: 2024-02-01

27	1,514	516710 16	477307 29
papers	citations	h-index	g-index

29	29	29	2615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolic disposition of H3B-8800, an orally available small-molecule splicing modulator, in rats, monkeys, and humans. Xenobiotica, 2020, 50, 1101-1114.	1.1	3
2	Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers. Cancer Chemotherapy and Pharmacology, 2019, 83, 91-96.	2.3	3
3	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERÎ± covalent antagonist (SERCA). Cancer Chemotherapy and Pharmacology, 2019, 83, 151-160.	2.3	18
4	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). Blood, 2019, 134, 673-673.	1.4	66
5	Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS ONE, 2018, 13, e0197372.	2.5	45
6	Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERÎ±WT and ERÎ±MUT Breast Cancer. Cancer Discovery, 2018, 8, 1176-1193.	9.4	81
7	H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma. Cancer Research, 2017, 77, 6999-7013.	0.9	100
8	Abstract DDT01-04: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer. Cancer Research, 2017, 77, DDT01-04-DDT01-04.	0.9	5
9	Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs. ACS Medicinal Chemistry Letters, 2016, 7, 797-801.	2.8	18
10	Structure and Property Guided Design in the Identification of PRMT5 Tool Compound EPZ015666. ACS Medicinal Chemistry Letters, 2016, 7, 162-166.	2.8	113
11	Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development. Drug Metabolism and Disposition, 2016, 44, 934-943.	3.3	26
12	Species differences in metabolism of EPZ015666, an oxetane-containing protein arginine methyltransferase-5 (PRMT5) inhibitor. Xenobiotica, 2016, 46, 268-277.	1.1	14
13	Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor. ACS Medicinal Chemistry Letters, 2016, 7, 134-138.	2.8	71
14	Structural and Kinetic Characterization of a Novel N-acetylated Aliphatic Amine Metabolite of the PRMT Inhibitor, EPZ011652. Drug Metabolism and Disposition, 2015, 43, 936-943.	3.3	7
15	A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nature Chemical Biology, 2015, 11, 432-437.	8.0	442
16	EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. ACS Medicinal Chemistry Letters, 2015, 6, 491-495.	2.8	107
17	Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound. ACS Medicinal Chemistry Letters, 2015, 6, 655-659.	2.8	105
18	Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor. Antimicrobial Agents and Chemotherapy, 2014, 58, 3233-3244.	3.2	88

#	Article	IF	Citations
19	Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma. Blood, 2014, 124, 438-438.	1.4	6
20	Assessment of CYP3Aâ€mediated drugâ€“drug interaction potential for victim drugs using an in vivo rat model. Biopharmaceutics and Drug Disposition, 2013, 34, 396-401.	1.9	11
21	Structure-based design of novel HCV NS5B thumb pocket 2 allosteric inhibitors with submicromolar gt1 replicon potency: Discovery of a quinazolinone chemotype. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4132-4140.	2.2	19
22	A simplified approach to predict CYP3A-mediated drugâ€“drug interactions at early drug discovery: validation with clinical data. Xenobiotica, 2013, 43, 592-597.	1.1	2
23	A strategy to reduce biliary clearance in early drug discovery. Journal of Pharmacological and Toxicological Methods, 2013, 68, 346-348.	0.7	1
24	A membrane vesicle-based assay to enable prediction of human biliary excretion. Xenobiotica, 2013, 43, 915-919.	1.1	8
25	A high throughputin vitromrp2 assay to predictin vivobiliary excretion. Xenobiotica, 2012, 42, 157-163.	1.1	14
26	The induction of cyclooxygenase-1 by a tobacco carcinogen in U937 human macrophages is correlated to the activation of NF-Î°B. Carcinogenesis, 2000, 21, 1745-1751.	2.8	70
27	Inhibition of Lung Tumorigenesis by Nsaids: A Working Hypothesis. Experimental Lung Research, 1998, 24, 605-615.	1.2	66